Opinion|Videos|May 12, 2025
Implementing Lp(a) Testing: Learning From LDL Testing and Considering Value-Based Care Models
Experts discuss lessons learned from implementing lipid-lowering therapy recommendations and explore the role value-based care models may play in successfully adopting the National Lipid Association’s (NLA) recommendation for lipoprotein(a) (Lp[a]) testing.
Advertisement
Video content above is prompted by the following:
In following the NLA recommendation, what lessons can we learn from our experience implementing recommendations for lipid-lowering therapies?
What role might value-based care models play in implementing the NLA recommendation?
Advertisement
Related to this article
Kidney Week 2026 brought strong IgAN data, looked back on 5 years of value-based kidney care, and highlighted evidence of persistent CKD care gaps.
Elagolix 150 mg was noninferior to dienogest 2 mg for reducing moderate-to-severe endometriosis pain in a phase 3 trial of 230 women in India.
Norah Terrault, MD, MPH, on why few diagnosed patients reach HCV cure and how primary care test-and-treat can close the gap.
Initial frontal fibrosing alopecia treatment was largely similar in Black and White patients, though tetracycline use was higher in Black patients.
An analysis of AccessHope case reviews found that experts recommended changes in more than 80% of cases. About half were implemented, saving a median of $18,636 per case.
Nearly half of patients with chronic HBV or HCV also had MASLD, tied to worse fatigue and quality of life.
From taladegib to admilparant and inhaled treprostinil, here are the key 2026 advances in idiopathic pulmonary fibrosis care.
Reductions in antibody function, not IgG titers, distinguishes efgartigimod responders in myasthenia gravis.
Advertisement
Advertisement
Trending on AJMC
1
HHS Draft Policy Eases Enforcement on 6 Compounded Peptides
2
BPC-157 'Wolverine Peptide' Use Rose 33-Fold Despite Scant Evidence
3
5 Things to Know About HHS's Interim Peptide Compounding Policy
4
Elagolix Noninferior to Dienogest for Endometriosis Pain in Phase 3 Trial
5